Redx Pharma (LSE:REDX) Change In Receivables : £-1.42 Mil (TTM As of Sep. 2023)

View and export this data going back to 2015. Start your Free Trial

What is Redx Pharma Change In Receivables?

Redx Pharma's change in receivables for the quarter that ended in Sep. 2023 was £-0.88 Mil. It means Redx Pharma's Accounts Receivable increased by £0.88 Mil from Mar. 2023 to Sep. 2023 .

Redx Pharma's change in receivables for the fiscal year that ended in Sep. 2023 was £-1.42 Mil. It means Redx Pharma's Accounts Receivable increased by £1.42 Mil from Sep. 2022 to Sep. 2023 .

Redx Pharma's Accounts Receivable for the quarter that ended in Sep. 2023 was £0.05 Mil.

Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed. Redx Pharma's Days Sales Outstanding for the six months ended in Sep. 2023 was 4.83.

In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. Redx Pharma's liquidation value for the six months ended in Sep. 2023 was £-4.15 Mil.

Redx Pharma Change In Receivables Historical Data

The historical data trend for Redx Pharma's Change In Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Redx Pharma Change In Receivables Chart

Redx Pharma Annual Data

Trend

Sep14

Sep15

Sep16

Sep17

Sep18

Sep19

Sep20

Sep21

Sep22

Sep23

Change In Receivables

Get a 7-Day Free Trial

0.45

-0.91

-4.65

7.63

-1.42

Redx Pharma Semi-Annual Data
	Mar14	Sep14	Mar15	Sep15	Mar16	Sep16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23
Change In Receivables	Get a 7-Day Free Trial															-4.25	8.69	-1.06	-0.55	-0.88

Redx Pharma Change In Receivables Calculation

Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.

Change In Receivables for the trailing twelve months (TTM) ended in Sep. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was £-1.42 Mil.

Redx Pharma (LSE:REDX) Change In Receivables Explanation

1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Redx Pharma's Days Sales Outstanding for the quarter that ended in Sep. 2023 is calculated as:

	Days Sales Outstanding
=	Accounts Receivable	/	Revenue	*	Days in Period
=	0.05	/	1.891	*	91
=	4.83

2. In Ben Graham's calculation of liquidation value, Redx Pharma's accounts receivable are only considered to be worth 75% of book value:

Redx Pharma's liquidation value for the quarter that ended in Sep. 2023 is calculated as:

	Liquidation Value
=	Cash, Cash Equivalents, Marketable Securities	-	Total Liabilities	+	(0.75 * Accounts Receivable)	+	(0.5 * Total Inventories)
=	18.092	-	22.281	+	0.75 * 0.05	+	0.5 * 0
=	-4.15

Redx Pharma Change In Receivables Related Terms

Thank you for viewing the detailed overview of Redx Pharma's Change In Receivables provided by GuruFocus.com. Please click on the following links to see related term pages.

Redx Pharma (LSE:REDX) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Redx Pharma PLC (LSE:REDX) » Definitions » Change In Receivables

Comparable Companies

Traded in Other Exchanges

N/A

Address

Block 33, Mereside, Alderley Park, Macclesfield, GBR, SK10 4TG

Website

https://www.redxpharma.com

Redx Pharma PLC is a United Kingdom-based biotechnology company focused on the development of novel precision medicines that have the potential to transform treatment in oncology and fibrotic diseases. Its product pipeline under development includes Porcupine Inhibitor, ROCK2 Selective Inhibitor, GI-targeted ROCK inhibitor, Pan-RAF Inhibitor, and others. The firm operates geographically in UK and Ireland. Revenue is generated from; Scientific programmes and research collaboration, Research collaboration and Research and preclinical development services. Redx is a clinical-stage biotechnology company focused on the discovery & development of novel, small-molecule, targeted medicines for the treatment of cancer and fibrotic disease and the emerging area of cancer-associated fibrosis.

Redx Pharma (LSE:REDX) Headlines

No Headlines